Gilead Sciences (NASDAQ:GILD) Earns “Neutral” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $70.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also issued reports on the company. BMO Capital Markets raised their price target on Gilead Sciences from $80.00 to $85.00 and gave the stock an outperform rating in a report on Friday, August 9th. Raymond James upgraded Gilead Sciences from a market perform rating to an outperform rating and set a $93.00 price target for the company in a research note on Monday, July 8th. Needham & Company LLC reiterated a hold rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Robert W. Baird reissued a neutral rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Finally, Evercore ISI upgraded shares of Gilead Sciences to a strong-buy rating in a research note on Friday, August 9th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $82.06.

Gilead Sciences Trading Down 0.6 %

GILD opened at $80.94 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $87.86. The business’s 50 day moving average is $74.82 and its two-hundred day moving average is $70.72. The firm has a market cap of $100.77 billion, a price-to-earnings ratio of 224.83, a price-to-earnings-growth ratio of 2.73 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. On average, research analysts predict that Gilead Sciences will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.81%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently modified their holdings of GILD. International Assets Investment Management LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $1,649,000. Gilbert & Cook Inc. grew its holdings in Gilead Sciences by 5.3% in the 4th quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock valued at $550,000 after buying an additional 344 shares during the period. Aveo Capital Partners LLC increased its stake in shares of Gilead Sciences by 8.6% during the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 435 shares during the last quarter. Principal Securities Inc. purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $561,000. Finally, Cary Street Partners Investment Advisory LLC boosted its position in shares of Gilead Sciences by 47.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 6,313 shares of the biopharmaceutical company’s stock worth $511,000 after acquiring an additional 2,024 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.